Taxol

DHW-221 was synthesized and purified as described previously (23 (link)). GDC-0980 and MG132 were obtained from Bide Pharmtech Ltd. (Shanghai, China). Taxol, docetaxel, vincristine, cisplatin, verapamil, and cycloheximide (CHX) were purchased from MedChem Express (NJ, USA). Rhodamine (Rho-123) and crystal violet were obtained from Shanghai Maclin Biochemical Co., Ltd. (Shanghai, China). Hoechst 33342 and 4,6-diamino-2-phenyl indole (DAPI) were obtained from Beyotime Biotechnology (Nanjing, China). The Annexin-V fluorescein isothiocyanate (FITC)/PI-double staining apoptosis detection kit and propidium iodide (PI) were obtained from Becton, Dickinson and Company (NJ, USA). P-gp antibody (CST, #13978; Rabbit, AF5185), PI3Kp110α antibody (rabbit, AF5112), p-FOXO3a (Ser253) antibody (rabbit, AF3020), and Bim antibody (Rabbit, AF0121) were purchased from Affinity Biosciences Pty Ltd. (Melbourne). Lactic dehydrogenase (LDH) detection kit (WL03271) and other primary antibodies were purchased from Wanlei Biotechnology Co., Ltd. (Shenyang, China)

The inducible BCL6 shRNA vectors were generated based on a pLVX-TetOne-Puro vector (RRID: Addgene 124797) according to standard protocols. All constructs were verified by sequencing. shRNAs sequence targeting BCL6 are available in Supplementary file 2. Recombinant human IFN-α1 (z02866) was purchased from Genscript (Nanjing, China). Recombinant IFN-γ (300-02) and anti-human IFN-γ antibody (506532) were purchased from PeproTech (Rocky Hill, USA). Etoposide (HY-13629, a topoisomerase II inhibitor), doxorubicin (HY-15142, a topoisomerase II inhibitor), cisplatin (HY-17394, a DNA synthesis inhibitor), carboplatin (HY-17393, a DNA synthesis inhibitor), taxol (HY-B0015, a microtubule association inhibitor), and gemcitabine (HY-17026, a DNA synthesis inhibitor) were purchased from MedChemExpress (Monmouth Junction, USA).